We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
ATRION Corporation | NASDAQ:ATRI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-4.00 | -0.96% | 413.20 | 404.60 | 405.69 | 422.05 | 412.51 | 412.51 | 16,769 | 16:33:45 |
Commenting on the Company’s results for the third quarter of 2018 compared to the same period last year, David A. Battat, President & CEO, said, “Aggregate revenue growth in all product lines excluding Ophthalmology was up 6%. The overall revenue growth of 4% was achieved despite a 23% decline in Ophthalmology as we are winding down certain products with contract and intellectual property expirations. This headwind will continue to impact our comparisons until the end of the first quarter of 2019. Net income and diluted EPS were both up 16% compared to last year’s third quarter.” Mr. Battat concluded, “During the quarter we added $4.3 million to our cash and short and long term investments bringing the total to $87 million as of September 30, 2018. We continue to be debt free.”
Atrion Corporation develops and manufactures products primarily for medical applications. The Company’s website is www.atrioncorp.com.
Statements in this press release that are forward looking are based upon current expectations and actual results or future events may differ materially. Such statements include, but are not limited to, Atrion’s expectations regarding the headwind from Ophthalmology sales until the end of the first quarter of 2019. Words such as “expects,” “believes,” “anticipates,” “intends,” "should", "plans," "will" and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements involve risks and uncertainties. The following are some of the factors that could cause actual results or future events to differ materially from those expressed in or underlying our forward-looking statements: changing economic, market and business conditions; acts of war or terrorism; the effects of governmental regulation; competition and new technologies; slower-than-anticipated introduction of new products or implementation of marketing strategies; the Company’s ability to protect its intellectual property; changes in the prices of raw materials; changes in product mix; and intellectual property and product liability claims and product recalls. The foregoing list of factors is not exclusive, and other factors are set forth in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements in this press release are made as of the date hereof, and we do not undertake any obligation, and disclaim any duty, to supplement, update or revise such statements, whether as a result of subsequent events, changed expectations or otherwise, except as required by applicable law.
Contact:Jeffery StricklandVice President and Chief Financial Officer(972) 390-9800
ATRION CORPORATIONUNAUDITED CONSOLIDATED STATEMENTS OF INCOME(In thousands, except per share data) | |||||||||||||||
Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | ||||||||||||||
2018 | 2017 | 2018 | 2017 | ||||||||||||
Revenues | $ | 39,274 | $ | 37,903 | $ | 117,522 | $ | 112,571 | |||||||
Cost of goods sold | 21,275 | 19,498 | 61,349 | 57,841 | |||||||||||
Gross profit | 17,999 | 18,405 | 56,173 | 54,730 | |||||||||||
Operating expenses | 7,242 | 6,926 | 22,784 | 21,749 | |||||||||||
Operating income | 10,757 | 11,479 | 33,389 | 32,981 | |||||||||||
Interest and dividend income | 439 | 287 | 1,157 | 806 | |||||||||||
Other investment income (loss) | 21 | -- | (1,153 | ) | -- | ||||||||||
Other income | 20 | -- | 20 | 1 | |||||||||||
Income before income taxes | 11,237 | 11,766 | 33,413 | 33,788 | |||||||||||
Income tax provision | (2,016 | ) | (3,795 | ) | (6,907 | ) | (5,841 | ) | |||||||
Net income | $ | 9,221 | $ | 7,971 | $ | 26,506 | $ | 27,947 | |||||||
Income per basic share | $ | 4.98 | $ | 4.30 | $ | 14.30 | $ | 15.16 | |||||||
Weighted average basic shares outstanding | 1,853 | 1,852 | 1,853 | 1,844 | |||||||||||
Income per diluted share | $ | 4.96 | $ | 4.29 | $ | 14.27 | $ | 15.06 | |||||||
Weighted average diluted shares outstanding | 1,858 | 1,857 | 1,857 | 1,856 | |||||||||||
ATRION CORPORATIONCONSOLIDATED BALANCE SHEETS(In thousands) | |||||
Sep 30, | Dec. 31, | ||||
ASSETS | 2018 | 2017 | |||
(Unaudited) | |||||
Current assets: | |||||
Cash and cash equivalents | $ | 50,031 | $ | 30,136 | |
Short-term investments | 15,465 | 35,468 | |||
Total cash and short-term investments | 65,496 | 65,604 | |||
Accounts receivable | 20,766 | 17,076 | |||
Inventories | 32,172 | 29,354 | |||
Prepaid expenses and other | 2,599 | 3,199 | |||
Total current assets | 121,033 | 115,233 | |||
Long-term investments | 21,166 | 9,136 | |||
Property, plant and equipment, net | 72,447 | 66,369 | |||
Other assets | 13,097 | 13,042 | |||
$ | 227,743 | $ | 203,780 | ||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||
Current liabilities | 11,987 | 9,622 | |||
Line of credit | -- | -- | |||
Other non-current liabilities | 10,599 | 9,770 | |||
Stockholders’ equity | 205,157 | 184,388 | |||
$ | 227,743 | $ | 203,780 |
1 Year ATRION Chart |
1 Month ATRION Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions